期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 137, 期 -, 页码 35-42出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2019.02.013
关键词
Immune-checkpoint inhibitors; Surrogate endpoints; Overall survival; Literature review
资金
- Bristol-Myers Squibb
Background: Surrogate endpoints (SEs) for overall survival (OS) are specific to therapeutic class. The objective of this review was to document all alternative endpoints studied for their association with OS in Immune Checkpoint Inhibitors (ICI)-treated patients. Methods: We searched PubMed and Embase for publications reporting the association between a clinical endpoint and OS in ICI-treated populations from 01/01/2003 to 03/31/2018. Results: Out of 6,335 references identified, 24 were selected. Only 3 studies assessed surrogacy at both the patient and trial levels. The main traditional alternative endpoints included progression-free survival (N = 10) and objective response rate (N = 8). New alternative endpoints, such as durable response rate (N = 1) and intermediate response endpoint (N = 1) statistically better correlate with OS in the cancer types analysed. Conclusion: Based on the published evidence, there is insufficient data to support validated SE for OS. Adequate surrogacy assessment of promising composite endpoints which consider a duration component is encouraged.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据